J. Kochenderfer

Oncology · 2010–2023

A researcher in the Science corpus: 10 papers; trusts 13 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 162 citations into it; #703 of 1,698 by trust here, #201 by citations
• Immunology — 85 citations into it
• Genetics — 64 citations into it; #5,329 of 6,854 by trust here, #3,220 by citations
• Hematology — 19 citations into it
• Biomedical Engineering — 9 citations into it; #8,291 of 10,734 by trust here, #2,804 by citations

Whom J. Kochenderfer trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. D. Porter
2. Jennifer N. Brudno
3. R. Brentjens
4. S. Maude
5. B. Levine
6. I. Rivière
7. R. Morgan
8. C. June
9. M. Dudley
10. Michel Sadelain

Who trusts J. Kochenderfer overall

1. Jennifer N. Brudno
2. C. June
3. Michel Sadelain
4. S. Rosenberg
5. Kathryn M. Cappell
6. Yiping Yang
7. R. Brentjens
8. S. Maude

Papers from J. Kochenderfer's perspective

Ordered by how strongly the researchers J. Kochenderfer trusts endorse each paper. Same corpus, a different order for every researcher.

1. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
2. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (Science Translational Medicine)
3. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells (Cancer Discovery)
4. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells (Nature Medicine)
5. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities (Nature Reviews Clinical Oncology)
6. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia (New England Journal of Medicine)
7. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial (The Lancet)
8. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia (New England Journal of Medicine)
9. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (New England Journal of Medicine)
10. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. (Blood)

Their papers

• Toxicities of chimeric antigen receptor T cells: recognition and management. (2016) — 1,293 citations
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. (2010) — 1,314 citations
• T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. (2016) — 722 citations
• Long-term outcomes following CAR T cell therapy: what we know so far (2023) — 1,115 citations
• Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma (2019) — 1,364 citations
• Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018) — 805 citations
• T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. (2018) — 652 citations
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. (2015) — 1,473 citations
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial (2014) — 2,727 citations
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. (2012) — 1,404 citations